Axogen to Participate at Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, and Peter Mariani, executive vice president and CFO will participate in upcoming investor conferences in November and December.
- Zaderej will participate in a fireside chat at the Jefferies London Healthcare Conference, on Tuesday, November 15, 2022 at 10:20 a.m. GMT, (5:20 a.m. ET).
- Mariani will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City on Thursday, November 17, 2022 at 8:30 a.m. ET.
- Zaderej will present at the Piper Sandler 34th Annual Healthcare Conference in New York City on Wednesday, November 30, 2022 at 10:30 a.m. ET.
- Zaderej and Mariani will participate in a panel discussion at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference in Miami, on Thursday, December 8, 2022 at 2:45 p.m. ET.
Webcasted events can be accessed live through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcasts, replays will be archived for 90 days and available through the Investors page on www.axogeninc.com.
Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Ed Joyce, Director, Investor Relations
Released November 3, 2022